Literature DB >> 19403315

Electrolyte disorders related to EGFR-targeting drugs.

Hassane Izzedine1, Rastilav Bahleda, David Khayat, Christophe Massard, Nicolas Magné, Jean Philippe Spano, Jean Charles Soria.   

Abstract

It is now clearly established that anti-vascular endothelial growth factor (VEGF) drug class induces hypertension and proteinuria sometimes related to thrombotic microangiopathy and/or various glomerulopathies, according to capillary and glomerular VEGF and VEGF-receptor expressions. As reported in the literature, anti-epidermal growth factor receptor (EGFR) therapies seem to be less nephrotoxic. Indeed, many reports of anti-EGFR nephrotoxicity are tubular dependent such as acute tubular necrosis, electrolyte disorders (hypophosphatemia, hypomagnesemia, etc.) or both. This is explained by elective tubular expression of renal EGF/EGFR. In this paper, we focus on electrolyte disorders related to anti-EGFR treatment and discuss the tubular involvement of these drugs based on their renal expression. Crown Copyright 2009. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19403315     DOI: 10.1016/j.critrevonc.2009.03.012

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  11 in total

1.  Effect of combined hormonal and insulin therapy on the steroid hormone receptors and growth factors signalling in diabetic mice prostate.

Authors:  Wagner J Fávaro; Valéria H A Cagnon
Journal:  Int J Exp Pathol       Date:  2010-10-05       Impact factor: 1.925

Review 2.  Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2017-05       Impact factor: 5.606

Review 3.  Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents.

Authors:  Andreia Costa; Sabine Tejpar; Hans Prenen; Eric Van Cutsem
Journal:  Target Oncol       Date:  2011-11-24       Impact factor: 4.493

Review 4.  Renal effects of targeted anticancer therapies.

Authors:  Camillo Porta; Laura Cosmai; Maurizio Gallieni; Paolo Pedrazzoli; Fabio Malberti
Journal:  Nat Rev Nephrol       Date:  2015-03-03       Impact factor: 28.314

Review 5.  The epidermal growth factor receptor pathway in chronic kidney diseases.

Authors:  Laura R Harskamp; Ron T Gansevoort; Harry van Goor; Esther Meijer
Journal:  Nat Rev Nephrol       Date:  2016-07-04       Impact factor: 28.314

Review 6.  Renal toxicity of anticancer agents targeting HER2 and EGFR.

Authors:  Laura Cosmai; Maurizio Gallieni; Camillo Porta
Journal:  J Nephrol       Date:  2015-09-04       Impact factor: 3.902

Review 7.  Nephrotoxicity of recent anti-cancer agents.

Authors:  Norbert Lameire
Journal:  Clin Kidney J       Date:  2013-11-26

Review 8.  Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review.

Authors:  Kenar D Jhaveri; Rimda Wanchoo; Vipulbhai Sakhiya; Daniel W Ross; Steven Fishbane
Journal:  Kidney Int Rep       Date:  2016-09-21

9.  Antibody-mediated inhibition of EGFR reduces phosphate excretion and induces hyperphosphatemia and mild hypomagnesemia in mice.

Authors:  Bernardo Ortega; Jason M Dey; Allison R Gardella; Jacob Proano; Deanna Vaneerde
Journal:  Physiol Rep       Date:  2017-03

10.  Pediatric onco-nephrology: time to spread the word : Part I: early kidney involvement in children with malignancy.

Authors:  Arwa Nada; Jennifer G Jetton
Journal:  Pediatr Nephrol       Date:  2020-11-27       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.